Medicenna Therapeutics (MDNAF) versus The Competition Financial Survey

Medicenna Therapeutics (OTCMKTS:MDNAF) is one of 458 public companies in the “Pharmaceutical Preparations” industry, but how does it contrast to its peers? We will compare Medicenna Therapeutics to related companies based on the strength of its institutional ownership, valuation, risk, dividends, earnings, profitability and analyst recommendations.

Volatility and Risk

Medicenna Therapeutics has a beta of 1.81, meaning that its stock price is 81% more volatile than the S&P 500. Comparatively, Medicenna Therapeutics’ peers have a beta of 5.43, meaning that their average stock price is 443% more volatile than the S&P 500.

Profitability

This table compares Medicenna Therapeutics and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Medicenna Therapeutics	N/A	-142.13%	-90.31%
Medicenna Therapeutics Competitors	-2,662.14%	-363.93%	-42.95%

Institutional & Insider Ownership

35.9% of Medicenna Therapeutics shares are owned by institutional investors. Comparatively, 39.1% of shares of all “Pharmaceutical Preparations” companies are owned by institutional investors. 33.1% of Medicenna Therapeutics shares are owned by company insiders. Comparatively, 13.9% of shares of all “Pharmaceutical Preparations” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of recent ratings and target prices for Medicenna Therapeutics and its peers, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medicenna Therapeutics	0	1	0	0	2.00
Medicenna Therapeutics Competitors	4898	9967	15991	376	2.38

As a group, “Pharmaceutical Preparations” companies have a potential upside of 63.59%. Given Medicenna Therapeutics’ peers stronger consensus rating and higher probable upside, analysts clearly believe Medicenna Therapeutics has less favorable growth aspects than its peers.

Valuation & Earnings

This table compares Medicenna Therapeutics and its peers gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Medicenna Therapeutics	N/A	-$8.48 million	-6.39
Medicenna Therapeutics Competitors	$431.82 million	-$67.77 million	-10.59

Medicenna Therapeutics’ peers have higher revenue, but lower earnings than Medicenna Therapeutics. Medicenna Therapeutics is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Summary

Medicenna Therapeutics peers beat Medicenna Therapeutics on 8 of the 13 factors compared.

Medicenna Therapeutics Company Profile

Medicenna Therapeutics Corp., a clinical stage immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. Its lead product is MDNA55, an interleukin- 4 (IL-4) EC that has completed Phase 2b clinical trial for the treatment of recurrent glioblastoma (rGBM), as well as preclinical and clinical development stages for the treatment of other brain and non-brain tumors. The company also develops MDNA55, which has completed Phase 2b clinical trial to treat rGBM; MDNA109, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease (GvHD); MDNA413, a dual IL-4/IL-13 antagonist to treat solid tumors; and MDNA132, an IL-13 Superkine to chimeric antigen receptor T (CAR-T) platform. In addition, it provides BiSKITs platform to develop designer Superkines by fusing them to other proteins, antibodies, or naked IL-2, IL-4, and IL-13 Superkines. Medicenna Therapeutics Corp. is headquartered in Toronto, Canada.